CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A

Nephrology Dialysis Transplantation

Volumn 23, Issue 6, 2008, Pages 2024-2032

  Abou Ayache, Ramzi ^a   Büchler, Mathias ^b   Lepogamp, Patrick ^c   Westeel, Pierre François ^d   Le Meur, Yannick ^e   Etienne, Isabelle ^f   Lobbedez, Thierry ^g   Toupance, Olivier ^h   Caillard, Sophie ⁱ   Goujon, Jean Michel ^a   Bergougnoux, Loïc ^j   Touchard, Guy ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f ROUEN UNIVERSITY HOSPITAL   (France)

^g CAEN UNIVERSITY HOSPITAL   (France)

^h REIMS UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^j Roche   (France)

more..

Author keywords

Cytomegalovirus; Daclizumab; Kidney transplantation; Thymoglobulin

Indexed keywords

CYCLOSPORIN A; DACLIZUMAB; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY;

ARTICLE; CADAVER; CELL COUNT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INCIDENCE; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; VIRUS INFECTION; VIRUS REPLICATION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, MONOCLONAL; CYCLOSPORINE; CYTOMEGALOVIRUS INFECTIONS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; REFERENCE VALUES; TREATMENT OUTCOME;

EID: 44449112273     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm873     Document Type: Article

References (34)

1. Vincenti F, Kirkman R, Light S et al. (Daclizumab Triple Therapy Study Group). Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161-165
2. Ekberg H, Persson NH, Källen R et al. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation. Scan J Immunol 2003; 58: 670-677
3. Hengster P, Pescovitz MD, Hyatt D et al. Cytomegalovirus infections after treatment with Daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Transplantation 1999; 68: 310-313
4. Kuypers DR, Evenpoel P, Maes B et al. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of low-dose tacrolimus and early withdrawal of steroid in renal transplant recipients. Clin Transplant 2003; 17: 234-241
5. Rostaing L, Cantarovich D, Mourad G et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807-814
6. Soulillou JP, Cantarovich D, Le Mauff B et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175-1182
7. Lebranchu Y, Bridoux F, Büchler M et al. Immunoprophylaxis with Basiliximab compared with Antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48-56
8. Brennan D, Daller J, Lake K et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967-1977
9. Mourad G, Rostaing L, Legendre C et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004; 78: 584-590
10. Abou-Jaoude MM, Ghantous I, Najm R et al. Daclizumab versus antithymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients. Transplant Proc 2003; 35: 2731-2732
11. Rasaiah S, Light J, Sasaki T et al. A comparison of daclizumab to ATGAM induction in simultaneous pancreas-kidney transplant recipients on triple maintenance immunosuppression. Clin Transplant 2000; 14: 409-412
12. Mullen JC, Oreopoulos A, Lien DC et al. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J Heart Lung Transplant 2007; 26: 504-510
13. Lischke R, Simonek J, Davidova R et al. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and anti-thymocyte globulin. Transplant Proc 2007; 39: 205-212
14. Burton CM, Andersen CB, Jensen AS et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. J Heart Lung Transplant 2006; 25: 638-647
15. Carlsen J, Johansen M, Boesgaard S et al. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. J Heart Lung Transplant 2005; 24: 296-302
16. Ekberg H, Backman L, Tufveson G et al. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transpl Int 2000; 13: 151-159
17. Nashan B, Light S, Hardie IR et al. Reduction of acute allograft rejection by daclizumab. Transplantation 1999; 67: 110-115
18. Hurault de Ligny B, El Haggan Wet al. Early loss of two renal grafts obtained from the same donor: role of ecstasy. Transplantation 2005; 80: 153-156
19. Webster AC, Playford EG, Higgins G et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77: 166-176
20. Bumgardner GL, Hardie I, Johnson RW et al. Results of three-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001; 72: 839-845
21. Pham K, Kraft K, Thielke J et al. Limited-dose daclizumab versus basiliximab: a comparison of cost and efficacy in preventing acute rejection. Transplant Proc 2005; 37: 899-902
22. Vanrenterghem V, Lebranchu Y, Hene R et al. Double blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 1352-1359
23. Funch DP, Walker AM, Schneider G et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5: 2894-2900
24. Abbud-Filho M, Adams PL, Alberu J et al. A report of the Lisbon Conference on the care of the kidney transplant recipient. Transplantation 2007; 83(Suppl 8): S1-S22
25. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ recipients. Am J Transplantation 2004; 4: 611-620
26. Morris JA, Hanson JE, Steffen BJ et al. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. Clin Transplant 2005; 19: 340-345
27. Ahsan N, Holman MJ, Jarowenko MV et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002; 2: 568-573
28. Ekberg H, Grinyo J, Nashan B et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am J Transplant 2007; 7: 560-570
29. Vincenti F. Interleukin-2 receptor antagonists and aggressive steroid minimization strategies for kidney transplant patients. Transplant Int 2004; 17: 395-401
30. Touchard G, Hauet T, Cogny van Weydevelt F et al. Maintenance cyclosporine monotherapy after renal transplantation: clinical predictors of long term outcome. Nephrol Dial Transplant 1997; 12: 1956-1960
31. Hurault de Ligny B, Toupance O, Lavaud S et al. F3actors predicting the long-term success of maintenance cyclosporine monotherapy after kidney transplantation. Transplantation 2000; 69: 1327-1332
32. Lebranchu Y, Aubert P, Bayle F et al. (M 55002 French Study Group). Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and cellcept? One-year results of a double-blind, randomized, multicenter study comparing normal dose versus low-dose and withdrawal of steroids. Transplant Proc 2000; 32: 396-397
33. Touchard G, Bridoux F, Etienne I et al. Efficacy and safety of maintenance Neoral monotherapy compared to bitherapy Neoral + MMF or Neoral + AZA in renal transplantation [abstract]. Am J Transplant 2005; 5(Suppl 11): S187
34. Meier-Kriesche HU, Kaza H, Palekar SS et al. The effect of daclizumab in a high-risk renal transplant population. Clin Transplant 2000; 14: 509-513